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    Postoperative nausea and vomiting (PONV) are common and 
distressing postsurgical symptoms [1] which continue to be a 
significant concern for anesthesiologists. PONV occurs in 20% 
to 30% of the general population underwent surgery and in up 
to 70% to 80% of high risk patients [2,3].
    PONV is a complex physiologic phenomenon involving 
multiple neurophysiologic pathways with both central and 
peripheral receptor mechanisms. A variety of factors have been 
associated with an increased incidence of postoperative nausea 
and vomiting. The most frequently described patient-specific 
risk factors for PONV are female gender, non-smokers, types 
of surgery such as laparoscopic surgery [4,5] or head and neck 
surgery, previous history of PONV or motion sickness, and use 
of intra-operative or postoperative opioids [3]. Postoperative 
analgesia with opioids is associated with an incidence of PONV 
of over 30% [6]. 
    Thyroidectomy is also associated with a relatively high 
incidence of PONV. The incidence of PONV after thyroidectomy 
has a reporting rate of 60-76% according to previous study [7]. 
PONV after thyroidectomy surgery might be the main source 
of discomfort, and it may be perceived as the most unpleasant 
aspect of postoperative recovery [8]. Being able to identify 
patient-specific risk factors should help clinicians determine 
appropriate prophylactic treatment for PONV.
    Many clinicians have used different types of anti-emetics 
such as anticholinergic drug, 5-hydroxytryptamine 3 (5-HT3) 
antagonist or NK-1 antagonist for the treatment of PONV. 
Ramosetron is a newly developed 5-HT3 receptors antagonist 
with a more potent and longer receptor antagonizing effect 
compared with other 5-HT3 receptors antagonists [9].
    In this issue of the Korean Journal of Anesthesiology, Lee 
et al. [10] report on the antiemetic effect of ramosetron with 
thyroi  dectomy for PONV. This clinical trial demonstrates the 
preventative effect of ramosetron for PONV in women under-
going total thyroidectomy with propofol-based total intravenous 
anesthesia (TIVA). The authors concluded that ramosetron was 
effective at reducing the incidence and severity of postoperative 
nausea in women that underwent total thyroidectomy with 
propofol-based TIVA during first 6 hours postoperatively. 
Nevertheless there are some debatable points in this paper. 
    The incidences of postoperative nausea in the control 
and the ramosetron groups were 29% and 12% during first 
6 postoperative hours respectively. From a statistical point 
of view, ramosetron is obviously more effective than control 
during first 6 postoperative hours (P = 0.029). But there were 
no differences between ramosetron and control (saline) after 
6 hours postoperatively. Also postoperative vomiting was 
not different all time periods on both groups. The incidence 
of PONV on the control group was not that high and widely 
different compared to the ramosetron group in this study as 
the authors mentioned. While many practitioners believe that 
5-HT3 antagonists are relatively safe medications, it is uncertain 
whether the antiemetic effects of 5-HT3 antagonists are better 
than inexpensive drugs such as droperidol or metoclopramide 
clinically. There is also uncertainty about benefit of ramosetron 
in patients undergoing TIVA.
    Cost-effective management is often referred to as an 
important medical issue. Recently, medical budgets are not 
sufficient for medical services of all patients in our country. 
Therefore, we need to be concerned about reduction of medical 
costs. In Korea, ramosetron (approximately US $55 for 0.3 mg) is 
much more expensive than other commonly used antiemetics, 
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such as metoclopramide.
    Many risk scoring systems for predicting PONV have been 
mentioned at present [3]. An evaluation of these risk factors 
allows clinicians to appropriately plan for prophylaxis and 
treatment of PONV. Eberhart suggests the use of simplified 
algorithms that could lead to a benefit for a larger proportion 
of patients [11]. Clearly, such a risk score-adapted preventive 
strategy for PONV may be viewed as an efficient method for 
PONV treatment.
    The first strategy in reducing the incidence of postoperative 
nausea and vomiting is to reduce the baseline risk factors for 
each patient. Patients with a low risk of PONV generally do not 
require prophylactic medication. Patients at moderate or high 
risk should receive antiemetic therapy with high cost-effective 
drugs. 
    Additionally, inexpensive and comprehensive multimodal 
managements for preventing PONV should be considered 
perioperatively. The use of propofol and the avoidance of 
nitrous oxide add to reductions of the incidence of PONV [12,13]. 
Other simple methods such as maintaining adequate hydration, 
minimizing the use of opioid analgesics for preventing post-
operative pain in high risk patients, and P-6 acupoint stimu-
lation [14] are also available.
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